Epizyme reported $2M in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbott ABT:US $ 4423M 520M
Amarin AMRN:US $ 30.21M 1.94M
Amgen AMGN:US $ 1609M 28M
Biogen BIIB:US $ 511.8M 52.1M
Bluebird Bio BLUE:US $ 19.7M 4.4M
Daiichi Sankyo 4568:JP Y 87407M 2255M
Eisai 4523:JP Y 40621M 1371M
Epizyme EPZM:US $ 2M 493K
Exelixis EXEL:US $ 11.87M 3.01M
Gilead Sciences GILD:US $ 1223M 167M
GlaxoSmithKline GSK:LN 2822M 303M
Glaxosmithkline GSK:US $ 2822M 303M
IONIS PHARMACEUT IONS:US $ 3M 0.04M
Karyopharm Therapeutics KPTI:US $ 589K 549K
MacroGenics MGNX:US 1.66M 1.64M
Merk MRK:US $ 3056M 14M
Novartis NOVN:VX SF 3848M 94M
Novartis NVS:US $ 3848M 94M
Pfizer PFE:US $ 9931M 2939M
Regeneron Pharmaceuticals REGN:US $ 453.2M 240.5M
Seattle Genetics SGEN:US $ 82.65M 4.56M
Vertex Pharmaceuticals VRTX:US $ 236.51M 8.54M